checkAd

     128  0 Kommentare CareDx to Report Fourth Quarter and Full Year 2020 Financial Results

    SOUTH SAN FRANCISCO, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it will report financial results for the fourth quarter and full year 2020 after market close on Wednesday, February 24, 2021. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

    Individuals interested in listening to the conference call may do so by dialing 877-705-6003 for domestic callers or 201-493-6725 for international callers. Please reference Conference ID: 13715410. To listen to a live webcast, please visit the investor relations section of CareDx’s website at: investors.caredxinc.com.

    About CareDx
    CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

    CONTACTS:
    Greg Chodaczek
    347-620-7010
    investor@caredx.com





    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    CareDx to Report Fourth Quarter and Full Year 2020 Financial Results SOUTH SAN FRANCISCO, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) - CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare …

    Schreibe Deinen Kommentar

    Disclaimer